LTR Pharma

Gain a direct line to LTR Pharma leadership.

Be first to know our latest company updates.

Watch exclusive videos accompanying major news.

Annual Reports

Investor Presentations

Announcements

Why Invest

Home

Corporate Governance

Corporate Directory

Board

Scientific Advisory Board

Company

Market Data

Shareholder Services

Shareholders

Montserrat

LTR Pharma Investor Centre

upload.jpg

Omega-3 oils are well known for their cardiovascular and anti-inflammatory benefits. However, published research confirms global demand already exceeds sustainable marine supply from marine harvesting, with overfishing, pollution and declining yields putting further pressure on supply. This growing imbalance is driving urgent demand for scalable, sustainable alternatives.

LevOmega has been co-founded by Levur, Green Blue Health, and LTR Pharma, combining expertise in biotechnology, nutraceuticals, and pharmaceutical commercialisation to develop nature-identical, pharmaceutical-grade omega-3 products.

Omega-3 oils are well known for their cardiovascular and anti-inflammatory benefits. However,  published research confirms global demand already exceeds sustainable marine supply from marine harvesting, with overfishing, pollution and declining yields putting further pressure on supply. This growing imbalance is driving urgent demand for scalable, sustainable alternatives.

For LTR Pharma, this collaboration complements the Company’s core intranasal pharmaceutical programs, including SPONTAN® and ROXUS®, while extending its innovation platform into a multi-billion-dollar global market.

LTR Pharma Executive Chairman, Lee Rodne, said:

"This investment highlights LTR’s ability to identify and secure transformative opportunities in large healthcare markets.  The omega-3 sector is a multi-billion-dollar market facing supply constraints, and LevOmega offers a scalable, sustainable solution.

“Our 33% stake, secured through strategic leadership rather than upfront capital, underlines the strength of LTR’s expertise and market position.  This partnership allows us to capture upside in the rapidly growing omega-3 market without diluting resources needed for our core therapeutic pipeline.”

LTR Pharma secures 33% ownership in LevOmega Pty Ltd